No Data
Express News | Amicus Therapeutics Inc : JP Morgan Cuts Target Price to $17 From $19
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a snapsh
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies a
Express News | Amicus Therapeutics Shares Are Trading Higher After Guggenheim Upgraded the Stock From Neutral to Buy and Announced a $13 Price Target
Express News | Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
Express News | Amicus Therapeutics Inc : Guggenheim Raises to Buy From Neutral